activates the central coagulation zymogen, prothrombin (ProT) and mediates cleavage of fibrinogen (Fbg) to fibrin (Fbn). Fbn generated in these reactions is thought to aid the bacteria in evading host immune cell defense mechanisms in acute bacterial endocarditis (2) .
We recently solved the crystal structure of the immediate human thrombin zymogen precursor, prethrombin 2 (Pre 2), bound to an SC fragment, SC-(1-325), which possesses full ProT activator and Fbg clotting activity (3, 4) . The structure demonstrates that SC activates ProT conformationally by a mechanism known as "molecular sexuality" (5) . Serine proteinase zymogens are activated normally by cleavage at Arg 15 -(Ile/Val) 16 activation sites (using the chymotrypsinogen numbering for the catalytic domain residues of serine proteinases). This cleavage liberates a new N terminus with a typical (Ile/Val) 16 -(Val/Ile) 17 sequence, which inserts into the "Ile 16 pocket" of the zymogen and forms a strong salt bridge with the Asp 194 carboxylate (5, 6) . Formation of this critical salt bridge triggers folding of the "activation domain" of the zymogen, resulting in formation of the substrate-binding site and oxyanion hole (7) . As postulated in the molecular sexuality hypothesis, the N-terminal SC- 17 N terminus in mature ␣-thrombin (8) . The SC-(1-325)⅐Pre 2 and thrombin structures raised questions concerning the nature of Fbg substrate recognition and cleavage by the SC-(1-325)⅐(pro)thrombin complexes because domain 2 (D2) of SC-(1-325) blocks exosite I, the Fbg recognition site.
Fbg is a large glycoprotein (M r ϭ ϳ340,000), formed by three pairs of A␣-, B␤-, and ␥-chains covalently linked to form a "dimer of trimers," where A and B designate the fibrinopeptides released by thrombin cleavage. The elongated molecule folds into three separate domains, a central fragment E that contains the N termini of all six chains and two flanking fragments D formed mainly by the C termini of the B␤-and ␥-chains. These globular domains are connected by long triple-helical structures (9 -11) . SC⅐(pro)thrombin complexes, which efficiently convert human Fbg to the self-polymerizing Fbn, are not targeted by circulating thrombin inhibitors (12, 13) . Thus, SC action bypasses the physiological blood coagulation pathway.
Fbg interactions with specific residues located in thrombin exosite I are required for fibrinopeptide removal and consequent Fbn generation (14, 15) . For example, the reversal-of-charge mutant Arg 73 3 Glu is severely compromised as a Fbg activator (16) . Further, variants in which alanine replaces residues Lys 70 , His 71 or Tyr 76 are practically devoid of * This work was supported by National Institutes of Health Grants HL038779 and HL071544 (to P. E. B.) and by the SPINE Project QLG2-CT-2002-00988 of the European Union and the Fonds der Chemischen Industrie (to W. B.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. 1 These authors contributed equally to this work. 2 Supported in part by National Institutes of Health Training Grant HL07751. 3 To whom correspondence should be addressed: Dept. Fbg clotting ability, and mutants Arg 73 3 Ala and Arg 77A 3 Ala possess Fbg clotting activities below 25% of wild-type thrombin (17) . Finally, occupancy of exosite I by the physiological regulator of the blood coagulation cascade, thrombomodulin (18, 19) , or by a thrombin-specific inhibitor, triabin (20) , impairs Fbg processing by competing with substrate binding.
Because the major Fbg recognition surface on ␣-thrombin is blocked in the SC-bound complexes, the mechanism of Fbg clotting by cofactorbound (pro)thrombin differs from that of the free enzyme. Investigation of the underlying mechanism was the goal of the present studies. Quantitation of interactions between Fbg and the SC-(1-325)⅐ProT complexes supports the conclusion that SC-(1-325) mediates specific Fbg binding and cleavage by expression of a new Fbg-binding exosite absent in the individual proteins. Molecular modeling of the complex formed between Fbg fragment E and the (SC-(1-325)⅐(pre)thrombin) 2 heterotetramer found in the crystals, together with results of equilibrium binding studies employing active site-labeled fluorescent ProT analogs described in the preceding paper (4), support the formation of a pentameric (SC-(1-325)⅐ProT) 2 ⅐Fbg complex, underpinning a novel cofactor-mediated mechanism of Fbg substrate recognition.
EXPERIMENTAL PROCEDURES
Protein Purification and Characterization-ProT and ␣-thrombin were purified and characterized as described previously (21) . Fbg (fraction I; Sigma) was purified further by chromatography on lysine-Sepharose to remove plasminogen, gelatin-Sepharose to remove fibronectin, and Sephacryl HR 400 to remove aggregates. Protein concentrations were determined by absorbance at 280 nm with the following absorption coefficients ((mg/ml) Ϫ1 cm Ϫ1 ) and molecular weights: ProT, 1.47, 71,600; thrombin, 1.74, 36,600; Fbg, 1.54, 340,000; and Met-SC-(1-325) and SC-(1-325), 1.00, 38,000 (4, 22, 23) . Fluorescent active site-labeled ProT analogs were prepared and characterized as described in the preceding paper (4). SC-(1-325) and Met-SC-(1-325) were expressed, purified, and characterized as described previously (3) . Dynamic Light Scattering-Laser light scattering experiments were performed by the use of fast protein liquid chromatography Superdex 200 HR10/30 gel filtration with in-line 90°light scattering measured by a PD2010 detector (Precision Detectors). Met-SC-(1-325) samples of 0.5 ml (5.1 mg/ml) were chromatographed at 0.75 ml/min in 50 mM Hepes, 125 mM NaCl, pH 7.4. Well resolved bovine serum albumin monomer, dimer, and trimer peaks were used to calibrate the detector for molecular weight determinations.
Analytical Equilibrium Ultracentrifugation-Sedimentation equilibrium experiments were performed with a Beckman XL-I ultracentrifuge equipped with UV-visible optics. The runs were performed at 0.1-0.3 mg/ml protein in 40 mM Hepes, pH 7.5, at varying salt concentrations. For determination of the molecular weight of the SC-(1-325)⅐(pre)thrombin complexes in solution, thrombin or Pre 2 were mixed with SC-(1-325) at a 1:1.1 molar ratio and subjected to centrifugation. The samples were centrifuged for 48 -72 h at 8°C at 9,000 rpm until equilibrium was reached, and the concentration gradient was scanned at 280 nm. The data were evaluated by calculating the partial specific volume from the amino acid composition. The data analysis was based on the assumption of a single species at equilibrium.
Fluorescence Studies-Fluorescence was measured with an SLM 8100 fluorometer, using polyethylene glycol 20,000-coated acrylic cuvettes. The experiments were performed in 50 mM Hepes, 110 mM NaCl 2 , 5 mM CaCl 2 , 1 mg/ml polyethylene glycol 8000, pH 7.4, at 25°C. Parallel measurements on blanks lacking the labeled species were used to correct for background. Binding of SC-(1-325) to various labeled ProT analogs was measured in titrations of labeled ProT monitoring the change in fluorescence at the following probe emission wavelengths (nm) of ProT labeled with: dansylaziridine (DAN), 506; 2-((4Ј-iodoacetamido)anilino)naphthalene-6-sulfonic acid (ANS), 438; 6-acryloyl-2-dimethylaminonaphthalene (ACR), 502; 6-bromoacetyl-2-dimethyl-aminonaphthalene (BAD), 510; the sulfonated coumarin derivative called AlexaFluor 350 C 5 maleimide (AF350), 436; BODIPY 507/545 iodoacetamide or N- (4,4-difluoro-1,3,5,7-tetramethyl-4- 
, and stoichiometric factor (n) the fitted parameters. Nonlinear least squares fitting was performed with SCIENTIST (MicroMath). The error estimates represent the 95% confidence interval.
Affinity Chromatography on Fbg-Agarose-Fbg-agarose (5.4 mg/ml gel) was prepared by coupling Fbg (fraction I; Sigma) to Affi-Gel 10 (Bio-Rad) according to the manufacturer's instructions. Fast protein liquid chromatography affinity chromatography on Fbg-agarose (0.9 ϫ 30 cm) was performed in 50 mM Hepes, 20 mM NaCl, 5 mM CaCl 2 , 1 mg/ml polyethylene glycol 8000, 0.1 M D-Phe-Pro-Arg-CH 2 Cl (FPR-CH 2 Cl), and D-Phe-Phe-Arg-CH 2 Cl, pH 7.4, at 25°C. The samples of 2 ml were loaded, and chromatography was performed at 0.5 ml/min, monitored by the 280-nm absorbance.
Native Gel Band Shift Experiments-Human Fbg was mixed with increasing concentrations of human or bovine SC-(1-325)⅐FPR-thrombin in 20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 2 mM CaCl 2 and incubated at room temperature for 15 min before adding sample buffer. Nondenaturing electrophoresis was performed with 6% polyacrylamide gels essentially following the standard Laemmli gel system but excluding SDS and 2-mercaptoethanol.
Binding of Fbg to SC-(1-325)⅐[5F]FPR-ProT or SC-(1-325)⅐[OG]FPRProT Complex-The fluorescence changes of [OG]FPR-ProT or
[5F]FPR-ProT in the presence of a slight molar excess of SC-(1-325) were measured in titrations with Fbg. 5 The data were analyzed by fitting a binding equation containing an additional term for the linear dependence of the fluorescence amplitude on the SC-(1-325)-labeled ProT complex concentration to account for a nonspecific fluorescence change. The observed fluorescence change is given by Equation 1,
where PL is the SC-(1-325)-labeled ProT⅐Fbg complex, P is the SC-( 31 segment through the active site cleft of each cognate enzyme, the resulting pentamer was subjected to a few energy refinement cycles with CNS (cnc.csb.yale.edu/) to avoid severe steric clashes. The (SC-(1-325)⅐Pre 2) 2 ⅐Fbg pentamer was constructed by optimally superimposing the central nodule of intact chicken Fbg (Protein Data Bank accession code 1JFE (11)) onto fragment E 5 .
RESULTS

Molecular Weights of SC-(1-325) and SC-(1-325)⅐Prethrombin 1 (Pre 1), Pre 2, and Thrombin Complexes-SC-(1-325)
was monomeric in solution as determined by fast protein liquid chromatography in-line laser light scattering, with a molecular weight of 38,500, in agreement with the calculated value and the value determined by mass spectrometry of 37,942. Sedimentation equilibrium experiments showed that SC-(1-325) complexed with thrombin or Pre 2 at physiological ionic strength, and pH had apparent molecular weights of 86,000 Ϯ 4,000, in agreement with formation of heterodimeric SC-(1-325)⅐(pre)thrombin complexes. Our previous finding that the SC-(1-325)⅐thrombin complex was tetrameric (3) was reproducibly obtained at low salt concentrations (20 mM KCl and below), where the apparent molecular weights increased considerably, indicating further, fully reversible aggregation to oligomers. Similar experiments performed with SC-(1-325) in the presence of Pre 2 showed similar salt-dependent self-association, but this was not observed for SC-(1-325)⅐Pre 1 complexes.
Interactions of Staphylocoagulase- with the Fbg Recognition Exosite- Fig. 1 shows an alignment of the crystallographically defined 1-281 sequence of SC from strain Tager 104, compared with sequences of SCs from different bacterial strains, which are representative of the distinct SC variants of S. aureus. In the SC-(1-325)⅐Pre 2 complex, each SC molecule consists of two independent, rod-like helical domains, D1 and D2 (3, 34) . The three-helix bundle of D2 covers the basic anion binding exosite I located to the "east" of the thrombin active site. In this major interaction site, the 70 -80 loop of thrombin grips into the groove formed by helices ␣ 2 D2 and ␣ 3 D2 and limited by the ␣ 1 D1 -␣ 2 Y loop, whereas helix ␣ 2 D2 slots into the thrombin exosite groove (Fig. 2) Recently, a crystal structure of Fbg fragment E bound to human thrombin was presented, which shows that the substrate primarily contacts residues of the 37 (e.g. Phe 34 and Ser 36A ), and 70 -80 loops (Tyr   76 and Arg 77A ) (36) . Surprisingly, SC domain D2 not only overlaps but turns out to bury a larger area of thrombin exosite I than the substrate Fbg (1,560 Å 2 compared with Ͻ1,200 Å 2 ). This finding implies that the clotting activity of SC-(1-325)⅐(pro)thrombin complexes does not rely on interactions of Fbg with this secondary binding exosite and prompted us to analyze in more detail the mechanism of Fbn generation by SC-bound (pro)thrombin.
SC-(1-325)⅐(Pre)thrombin Complexes Crystallize as Symmetric Dimers-
The SC-(1-325)⅐(pre)thrombin crystals contain two tightly interdigitating heterodimeric complexes/asymmetric unit (Fig. 3A) . Both complexes can almost exactly be superimposed by a rotation of 180°, i.e. they are related by a virtually exact but crystallographically local 2-fold rotation axis. In this symmetric homodimer, the active sites of the two (pre)thrombin molecules face the central intermonomer space, with their active site Ser 195 residues separated by about 75 Å. Upon complex dimerization, an elongated interface of 1,300 Å 2 is removed from contact with bulk solvent. In its center, the ␣ 0 D1 -␣ 1
D1
turns ( SC Thr 20 and SC Leu 21 ) oppose each other to form a hydrophobic bridge (Fig. 3B) . This bridge is, however, surrounded by a number of water molecules, which cross-connect polar groups from both monomers. Further, the C-terminal ends of helices ␣ 2 D1 and the following ␣ 2 D1 -␣ 3 D1 segments protrude out of the helix bundles and form fingerlike structures, each of which covers the N-terminal part of helix ␣ 1 D1 from the neighboring monomer. These fingers carry a number of highly conserved aromatic residues (e.g. SC (1-325) , ProT, and Fbg-In light of the SC-(1-325) blockade of exosite I and to address the mechanism of Fbg recognition by SC-(1-325)⅐(pro)thrombin complexes, we first examined interactions of ProT, Met-SC-(1-325), and Met-SC-(1-325)⅐ProT with Fbg by affinity chromatography on Fbg-agarose. ProT eluted in the void volume, indicating no detectable interaction (Fig. 4A) , and Met-SC-(1-325) eluted in a trailing peak in the low ionic strength (0.05 M) equilibration buffer and fully at 4 M NaCl, suggestive of weak binding. Chromatography of an equimolar mixture of ProT and Met-SC-(1-325), in contrast, resulted in depletion of the free ProT and Met-SC-(1-325) peaks and appearance of a new Met-SC-(1-325)⅐ProT peak eluted with NaSCN (Fig. 4A) . The results indicated that Met-SC-(1-325) bound to ProT and generated a Fbg-binding site not present on either of the individual components that mediated high affinity ternary complex formation. Band shift studies using native polyacrylamide-gel electrophoresis were also performed to confirm Fbg binding by the SC-(1-325)⅐FPR-thrombin complexes and to give initial estimates of (34)). The figure was prepared using PYMOL (35) . substrate to complex ratios. In these qualitative assays, no interaction was detected between free SC-(1-325) and Fbg, whereas the complex of SC-(1-325) and FPR-CH 2 Cl-substituted thrombin was band-shifted in the presence of both human ( Because SC-(1-325) alone does not bind tightly to Fbg, and the two major binding sites on thrombin, namely the active site cleft and exosite I, are blocked in the SC-(1-325)⅐FPR-thrombin complex without impairing Fbg binding, we conclude that complex formation is essential for development of a Fbg-specific, high affinity binding site. In principle, this new binding site could be induced in either moiety upon complex formation. There are, however, no noticeable changes in SC-bound thrombin compared with other reported crystal structures, aside from those regions involved in direct contact with the cofactor. In this regard, SC binding results in only minor changes in thrombin specificity against small molecule substrates, including those corresponding to the cleavage site sequences for fibrinopeptides A and B (4). This indicated that specificity for Fbg was not dictated by localized active site interactions with the S1-S3 6 specificity sites. A second possibility was that a new docking site is exposed in the SC moiety. Although the structure of free SC-(1-325) remains unknown, its relatively simple architecture would seem to preclude major reorganizations within the helical domains such as rotation of one helix relative to the others or bending of these rod-like domains. A displacement of domains D1 and D2 relative to each other cannot be excluded but seems to be at odds with the observed interactions at the interdomain interface (see above and Fig. 3B ). Finally, a change in quaternary structure might be responsible for the increase in affinity. Indeed, as shown above, whereas both SC-(1-325) and (pre)thrombin are monomers in solution, the SC-(1-325)⅐(pre)thrombin complexes crystallize as symmetric dimers (Fig. 3A) . We thus hypothesized that Fbg binding may involve formation of a bivalent species, because it would provide a straightforward means to increase substrate affinity and specificity.
Screening of Fluorescent ProT Analogs for Reporters of Fbg Binding-To evaluate the above hypothesis, the array of ProT analogs described in the preceding paper (4) 
A Model of Fbg Recognition by the SC-(1-325)⅐(Pro)thrombin Complex-
The stoichiometry determined in the above studies indicated that a dimeric (SC-(1-325)⅐(pre)thrombin) 2 complex similar to the one found in the crystals could bind symmetrically to a single Fbg dimer, with the possibility of cleaving both fibrinopeptides A simultaneously. Besides structures of a proteolytically truncated bovine (9) and an intact chicken Fbg molecule (11), two high resolution structures of a bovine fragment E 5 recently became available (25) , which allowed reasonable docking experiments. The (quasi)dimeric fragment E 5 consists of a central domain including the six N-terminal Fbg segments and two lateral rod-like domains, comprising the C-terminal segments of the constituting chains (␣, ␤, ␥, ␣Ј, ␤Ј, and ␥Ј) wound around each other in a coiled-coil arrangement. The E 5 molecule lacks the first 25 (human A␣) and 60 (B␤) amino acid residues, respectively, and the first six ␣-chain residues physically contained (equivalent to HumA␣ Ser 26 -HumA␣ Thr 31 ) are disordered in both crystal forms. On one side of the central E 5 domain, the N-terminal ␣-chain segments form a knob-like projection, whereas on the opposite side the defined N-terminal seg- ments of the ␣-and ␤-chains cluster, creating the wall of a "funnel." Both ␣-chain N termini are disulfide-linked via their HumA␣ Cys 28 residues within the inner hydrophobic depression of this funnel.
Manual docking experiments of the fragment E 5 structure against our dimeric (SC-(1-325)⅐Pre 2) 2 structure revealed optimal interactions when both pseudo-2-fold axes were colinear (Fig. 7 ). In the model, both elongated components cross each other at an angle of about 30°, and the fragment E funnel, including the disordered N-terminal B␤-chain, packs against the central SC-SC interface (Fig. 7) . The location of the ␣C domains of full-length Fbg is unknown because they are completely absent in the chicken Fbg crystal structure because of disorder (11) . Electron microscopy studies suggest that these domains interact with each other and with fragment E in Fbg and dissociate in Fbn (37) . The uncertain location of these domains and their high mobility suggest that they may not collide with the cognate SC-(1-325)⅐(pro)thrombin complexes. The observed packing leaves an "internal" cavity between the E 28 disulfide bridge) such that the preceding residues HumA␣ Gly 17 -Arg 19 could slot into the prime side "exit" channel between thrombin loops 37 and 60 (Fig. 7) , as previously shown or suggested (14, 38) . Simultaneously, the fibrinopeptide A segment HumA␣ Asp 7 -Arg 16 could bind into the non-prime subsites, presenting both scissile HumA␣ Arg 16 -Gly 17 peptide bonds to the two prothrombin catalytic centers for efficient simultaneous cleavage.
DISCUSSION
The results of equilibrium binding studies and molecular modeling demonstrate a novel mechanism of Fbg substrate recognition and cleavage by the conformationally activated SC-(1-325)⅐(pro)thrombin complexes that is dominated by expression of a new Fbg-binding exosite on the SC complexes. Screening of ProT analogs allowed their use to quan- The changes in specificity brought about by nonproteolytic bacterial activators of serine proteinase zymogens represent one of their most remarkable peculiarities. For example, Pg and Pm bound to streptokinase (SK) and Pm bound to staphylokinase (SAK) potently activate free Pg molecules proteolytically, a capability that free Pm does not possess. Our crystal structure of the ternary complex of SAK bound to two catalytic domains of Pm, one of which mimics the Pg substrate molecule, revealed a specific Pg-docking site on the cofactor moiety (39) . In addition, the newly formed SAK Lys 10 N terminus appears to interact with a regulatory kringle domain of the substrate Pg (40) . Although similar structural evidence is missing for the SK⅐Pg/Pm complexes, the results of recent investigations demonstrate that Pg substrate binding is mediated by expression of a new exosite on the SK⅐Pm complex (41) and is facilitated by interaction of specific lysine residues of the bacterial cofactor with kringle domain(s) of the substrate Pg molecule (42) (43) (44) (45) .
Similar to the emergence of Pm specificity for Pg as a substrate on binding to SK and SAK and the resistance of these complexes to inactivation by antiplasmin and other serpins, SC⅐ProT has equivalent Fbg clotting activity as ␣-thrombin (4) but, as shown here, binds Fbg with greatly increased affinity, suggesting an increased specificity for Fbg. The substrate specificity of SC (1-325)⅐(pro)thrombin complexes is highly restricted to Fbg, with the complexes exhibiting little or no activity toward other physiological thrombin substrates and inhibitors, such as factors V and VIII, protease-activated receptors, antithrombin, and other serpins. The affinity of the SC-(1-325)⅐ProT complex for Fbg is ϳ200 -900-fold higher than the exosite I-driven K m of 7.2 M for ␣-thrombin cleavage of Fbg (46), which circulates under physiologic conditions at 8.8 M (3 mg/ml). Resistance of the catalytic activity of SC-(1-325)⅐(pro)thrombin complexes to inactivation by physiologic ␣-thrombin inhibitors is thought to contribute to unregulated Fbn formation during acute bacterial endocarditis. In the microenvironment of a platelet-Fbn-bacteria vegetation produced in endocarditis, formation of the high affinity SC⅐ProT complex would clearly predominate, resulting in rapid, localized Fbn deposition.
Paradoxically, the major Fbg recognition surface on thrombin is completely blocked by SC domain D2 and is therefore not available for interaction with the negatively charged segments of the Fbg ␣-chain downstream of the A␣ Arg 16 -A␣ Gly 17 scissile peptide bonds. This is substantiated by our solution studies demonstrating the protection of the Fbg clotting activity of SC-(1-325)⅐(pro)thrombin from inhibition by the exosite I-specific ligand, Hir-(54 -65)(SO 3 Ϫ ) and displacement of a fluorescein-labeled derivative of the peptide by SC-(1-325) and SC D2 binding (3, 4) . This puzzling observation implies that Fbg presentation to the thrombin active site is taken over by the bacterial cofactor mechanistically similar to interactions of substrate Pg with SK and SAK.
The current results show that SC-(1-325) exhibits low affinity for Fbg. This fully active cofactor fragment binds Fbg with high affinity only in its complex with (pro)thrombin. This feature might be caused by changes in either SC-(1-325) or (pro)thrombin to expose a cryptic binding site on complex formation, but such rearrangements appear unlikely in the light of current structural evidence. The fact that SC-(1-325)⅐(pre)thrombin crystals are formed by symmetric dimers immediately suggests a simpler explanation for these observations, namely that two complex molecules bind simultaneously to the intrinsically dimeric Fbg molecule. In this manner, a relatively weak intermolecular interaction is enhanced extraordinarily through multimerization. Our modeling studies suggest that Fbg fragment E would obliquely dock into the large groove between the two SC-(1-325)⅐(pre)thrombin heterodimers, with its central funnel-like domain packed against the SC-SC interface. In this arrangement, the two bound (pre)thrombin molecules are properly placed to simultaneously bind and cleave the fibrinopeptides A of substrate Fbg. Of course, our model is not the sole possible arrangement of the pentameric complex but is very attractive given the fact that in our crystallographic dimers the active sites of (pre)thrombin face each other at a distance of about 75 Å, into which a Fbg molecule can be perfectly docked. The ␣-chain interaction with SC⅐(pro)thrombin thus differs considerably from that anticipated for the physiological thrombin-Fbg encounter complex (47) (14, 15) , has been mapped on the thrombin side by site-directed mutagenesis (16, 17) and roughly overlaps with the interaction areas of exosite I-binding proteins such as thrombomodulin (18) and triabin (20) . In the SC-(1-325)⅐(pre)thrombin complexes, exosite I is occupied by the D2 domain of the SC-(1-325) molecule, so that it is not available for interaction with the negatively charged ␣-chain segments downstream of the Fbg scissile bonds. Presumably, the fixation of these ␣-chain peptides, believed to be essential for the correct presentation of the scissile peptide bond to the thrombin active site, is taken over by their proper packing against the SC-SC and/or SC-Fbg interfaces.
An important element of our model of Fbg recognition and cleavage by SC⅐(pro)thrombin complexes is their ability to dimerize. Whereas this is unambiguous in the crystal structures, ultracentrifugation results indicate that this does not occur to a significant extent in solution at the concentrations studied. Moreover, in ultracentrifugation studies, the SC-(1-325)⅐thrombin complex oligomerized at low salt concentrations but was monomeric at the more physiological conditions used in the equilibrium binding studies. Further, we observed dimer-oligomer formation of SC-(1-325)⅐thrombin or Pre 2 complexes but not of complexes formed with Pre 1. On the basis of these observations, we conclude that the pentameric Fbg complex is probably assembled by binding of two SC-(1-325)⅐(pro)thrombin complexes to Fbg and that this complex is stabilized by interactions between SC D1 domains like those documented in the crystal structures.
Finally, we note that additional interactions between full-length SC and Fbg might strengthen substrate binding to the SC⅐ProT complex. First, it is conceivable that the C-terminal SC-(1-325) segment SC Glu 282 -SC Leu 325 , which is disordered in the crystal structures of the SC-(1-325)⅐(pre)thrombin complexes, interacts with N-terminal domains of the cognate ProT or with Fbg. Its rather high degree of sequence conservation would be difficult to understand otherwise. Second and perhaps more importantly, recent findings on another Fbgbinding protein secreted by S. aureus, Efb, suggest Fbg binding is mediated by the C-terminal SC repeat sequences (residues SC Ala 467 -SC Gly 655 in the variant used in this study) (48, 49) . Efb competes with SC for Fbg by interacting with fragment D through two independent binding sites. The N-terminal binding site in Efb comprises two tandem repeats similar to the five to eight homologous peptides found in different SCs. Thus, these C-terminal tandem repeats of SC are expected to bind to Fbg fragment D and contribute to Fbg clotting, explaining Efb inhibition of SC activity (49) . In support of this, full-length SC containing seven repeats binds to isolated fragment D of human Fbg. 7 In conclusion, our results resolve the paradox that occupation of thrombin exosite I by SC leads to increased and restricted specificity of (pro)thrombin for its substrate, Fbg. SC presents specific docking sites for the zymogen (ProT) as well as for the substrate (Fbg), which are thus brought together in a multimeric encounter complex to allow optimal substrate processing. This mechanism is similar to the one employed by bacterial Pg activators, SK and SAK (39, 40, (42) (43) (44) (45) 50) , and also to the physiological thrombin modulator, thrombomodulin (18) . Future mutagenesis and structural investigations will disclose SC residues involved in interactions with Fbg, which might open new avenues for the treatment of staphylococcal infections.
